Metabolic therapy for heart disease: impact of trimetazidine.
Sabbah
Hani N
HN
Department of Medicine, Division of Cardiovascular Medicine, Henry Ford Heart and Vascular Institute, Detroit, Michigan 48202, USA. HSABBAH1@hfhs.org
Stanley
William C
WC
D002334:Carnitine O-Palmitoyltransferase / Q000037:antagonists & inhibitors / Q000187:drug effects / Q000378:metabolism; D005227:Fatty Acids / Q000378:metabolism; D006331:Heart Diseases / Q000188:drug therapy* / Q000378:metabolism*; D006801:Humans; D008066:Lipolysis / Q000187:drug effects; D010084:Oxidation-Reduction; D014292:Trimetazidine / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*
D005227:Fatty Acids; D014665:Vasodilator Agents; D002334:Carnitine O-Palmitoyltransferase; D014292:Trimetazidine